Evidence map›Paper›PMID 37108826›Full record

ArticleInternational journal of molecular sciences2023

TDP-43 Controls HIV-1 Viral Production and Virus Infectiveness.

Romina Cabrera-Rodríguez, Silvia Pérez-Yanes, Iria Lorenzo-Sánchez, Judith Estévez-Herrera, Jonay García-Luis, Rodrigo Trujillo-González, Agustín Valenzuela-Fernández

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Review
  3. CRISPR/Cas9-MediatedAnimals : an open access journal from MDPI · 2025
    Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Implications of TDP-43 in non-neuronal systems.Cell communication and signaling : CCS · 2023
    Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Romina Cabrera-RodríguezLaboratorio "Inmunología Celular y Viral", Unidad de Farmacología, Sección de Medicina, Facultad de Ciencias de la Salud, Universidad de La Laguna (ULL), 38320 La Laguna, Tenerife, Spain.ORCID 0000-0001-5671-6196
Silvia Pérez-YanesLaboratorio "Inmunología Celular y Viral", Unidad de Farmacología, Sección de Medicina, Facultad de Ciencias de la Salud, Universidad de La Laguna (ULL), 38320 La Laguna, Tenerife, Spain.
Iria Lorenzo-SánchezLaboratorio "Inmunología Celular y Viral", Unidad de Farmacología, Sección de Medicina, Facultad de Ciencias de la Salud, Universidad de La Laguna (ULL), 38320 La Laguna, Tenerife, Spain.
Judith Estévez-HerreraLaboratorio "Inmunología Celular y Viral", Unidad de Farmacología, Sección de Medicina, Facultad de Ciencias de la Salud, Universidad de La Laguna (ULL), 38320 La Laguna, Tenerife, Spain.
Jonay García-LuisLaboratorio "Inmunología Celular y Viral", Unidad de Farmacología, Sección de Medicina, Facultad de Ciencias de la Salud, Universidad de La Laguna (ULL), 38320 La Laguna, Tenerife, Spain.ORCID 0000-0002-2799-7491
Rodrigo Trujillo-GonzálezLaboratorio "Inmunología Celular y Viral", Unidad de Farmacología, Sección de Medicina, Facultad de Ciencias de la Salud, Universidad de La Laguna (ULL), 38320 La Laguna, Tenerife, Spain.ORCID 0000-0001-7321-5430
Agustín Valenzuela-FernándezLaboratorio "Inmunología Celular y Viral", Unidad de Farmacología, Sección de Medicina, Facultad de Ciencias de la Salud, Universidad de La Laguna (ULL), 38320 La Laguna, Tenerife, Spain.ORCID 0000-0002-2585-8703
Universidad de La Laguna · ES

Funding

Agencia Canaria de Investigación, Innovación y Sociedad de la Información" and European So-cial Fund ProID2020010093Juan de la Cierva de Incorporación" Spanish Program ("Ayudas Juan de la Cierva de incorporación; AEI/MCIN"). IJC2019-038902-IMinisterio de Ciencia e Innovación")/AEI ("Agencia Española de Investi-gación")/10.13039/501100011033/FEDER, UE) (Spain) PID2021-123031OB-I00Ministerio de Ciencia, Innovación y Universidades", Spain RTI2018-093747-B-100Ministerio de Ciencia, Innovación y Universidades, Spain Contrato Predoctoral Ministerio-ULL Formación de Doctores" (2019 Program)SEGAI-ULL SEGAI-ULLSpanish AIDS network "Red Temática Cooperativa de Investigación en SIDA", as part of the Plan Nacional R+D+I and cofunded by Spanish "Instituto de Salud Carlos III (ISCIII)-Subdirección General de Evaluación y el Fondo Europeo de Desarrollo Regional (FED- RD16/0025/0011The European Regional Development Fund (ERDF) and "Fundación CajaCanarias" UNLL10-3E-783
6 · The paper itself

Abstract

The transactive response DNA-binding protein (TARDBP/TDP-43) is known to stabilize the anti-HIV-1 factor, histone deacetylase 6 (HDAC6). TDP-43 has been reported to determine cell permissivity to HIV-1 fusion and infection acting on tubulin-deacetylase HDAC6. Here, we studied the functional involvement of TDP-43 in the late stages of the HIV-1 viral cycle. The overexpression of TDP-43, in virus-producing cells, stabilized HDAC6 (i.e., mRNA and protein) and triggered the autophagic clearance of HIV-1 Pr55

Indexed as

DNA-Binding ProteinsGene Products, gagProtein Processing, Post-TranslationalRNA, MessengerDNA-Binding ProteinsGene Products, gagRNA, MessengerautophagyHDAC6HIV-1 infection capacityTARDBP/TDP-43viral production

Identifiers

PMID37108826
PMCPMC10142003
OpenAlexW4366773513

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.